I was invested in a small biotech in 2015 that did a reverse split and uplisted during the lead up to a big data release. At the top of the PPS, which was around $15, it was a 7 bagger if you had gotten in just 5-6 months before. At this point in CYDY it’s hard to say exactly when the company will have a similar moment, it it may be with a partnership, FDA approval, approval for mono therapy or good TNBC data.